Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)
1 Prospective Clinical Study Committee of Anaplastic Thyroid Carcinoma Research Consortium of Japan, Headquarter in the Department of Endocrine Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
2 Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
3 Department of Endocrine Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
4 Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe-shi 650-0011, Hyogo, Japan
5 Department of Breast and Endocrine Surgery, Tsukuba University, 1-1-1 Tenno-dai, Tsukuba-shi 305-0006, Ibaragi, Japan
6 Department of Surgery II, Shinshu University, 3-1-1 Asahi, Matsumoto-shi, Nagano 390-8621, Japan
7 Kanaji Hospital, 1-5-6 Nakazato, Kita-ku, Tokyo 114-0015, Japan
8 Ito Hospital, 4-3-6 Jingu-mae, Shibuya-ku, Tokyo 150-8308, Japan
9 Department of Thyroid and Endocrinology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan
10 Division of Head and Neck, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
11 Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama-shi 241-8515, Kanagawa, Japan